MAPT and Alzheimer disease: In this retrospective study, we aimed to explore the relationship between the CSF p-tau/Aβ42 biomarkers typically used for the in vivo diagnosis of AD according to the NIA-AA Framework for AD diagnosis through biomarkers [1,2] and the topography and individual frequency bands of rsEEG rhythms in ADMCI patients compared to those with MCI not attributed to AD (noADMCI).